上海环码生物医药

CircuCode is a Shanghai-based biotechnology company dedicated to the development of next-generation circular RNA (circRNA) therapeutics. The company leverages a proprietary platform to design circRNA molecules that offer significant advantages over linear mRNA, including enhanced stability, reduced immunogenicity, and prolonged protein expression. Their research focuses on high-impact therapeutic areas such as oncology, rare diseases, and infectious disease vaccines. By optimizing the internal ribosome entry site (IRES) and circularization processes, CircuCode aims to create a versatile drug development engine. The company is supported by leading venture capital firms and is positioned at the forefront of the RNA medicine revolution in Asia.